Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Nuclear Cardiology
Erschienen in: Journal of Nuclear Cardiology 1/2022

10.07.2020 | ORIGINAL ARTICLE

Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera

verfasst von: Quentin Brana, Frédérique Thibault, MD, Maxime Courtehoux, MD, Gilles Metrard, MD, Maria Joao Ribeiro, MD, PhD, Denis Angoulvant, MD, PhD, Matthieu Bailly, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Regadenoson is a selective adenosine receptor agonist. It is currently unclear if the level of hyperemia differs between stress agents. We compared Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) response on CZT-SPECT Myocardial Perfusion Imaging (MPI) to evaluate if dipyridamole and regadenoson could induce the same level of hyperemia.

Methods

228 patients with dynamic CZT-SPECT MPI were retrospectively analyzed (66 patients stressed with regadenoson and 162 with dipyridamole) in terms of MBF and MFR. To rule out confounding factors, two groups of 41 patients were matched for clinical characteristics in a sub-analysis, excluding high cardiovascular risk patients.

Results

Overall stress MBF was higher in regadenoson patients (1.71 ± 0.73 vs. 1.44 ± 0.55 mL·min−1·g−1 for regadenoson and dipyridamole, respectively, p < .05). However, when confounding factors were ruled out, stress MBF (1.57 ± 0.56 vs. 1.61 ± 0.62 mL·min−1·g−1 for dipyridamole and regadenoson, respectively, p = .88) and MFR (2.62 ± 0.77 vs. 2.46 ± 0.76 for dipyridamole and regadenoson, respectively, p = .40) were not different between regadenoson and dipyridamole.

Conclusions

Our results suggest that dipyridamole and regadenoson induce equivalent hyperemia in dynamic SPECT with similar stress MBF and MFR in comparable patients.
Literatur
1.
Johnson SG, Peters S. Advances in pharmacologic stress agents: Focus on regadenoson. J Nucl Med Technol 2010;38:163-71.PubMed
2.
Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36.PubMed
3.
Page RL, Spurck P, Bainbridge JL, Michalek J, Quaife RA. Seizures associated with regadenoson: A case series. J Nucl Cardiol 2012;19:389-91.PubMed
4.
Druz RS. Current advances in vasodilator pharmacological stress perfusion imaging. Semin Nucl Med 2009;39:204-9.PubMed
5.
Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.PubMed
6.
Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68.PubMed
7.
Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM, et al. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: A quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol 2015;22:248-61.PubMed
8.
Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.PubMed
9.
Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. JACC Cardiovasc Imaging 2012;5:1014-21.PubMed
10.
Golzar Y, Doukky R. Regadenoson use in patients with chronic obstructive pulmonary disease: The state of current knowledge. Int J Chron Obstruct Pulmon Dis 2014;9:129-37.PubMedPubMedCentral
11.
Hussain N, Chaudhry W, Ahlberg AW, Amara RS, Elfar A, Parker MW, et al. An assessment of the safety, hemodynamic response, and diagnostic accuracy of commonly used vasodilator stressors in patients with severe aortic stenosis. J Nucl Cardiol 2017;24:1200-13.PubMed
12.
Rai M, Ahlberg AW, Marwell J, Chaudhary W, Savino JA, Alter EL, et al. Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers. J Nucl Cardiol 2017;24:724-34.PubMed
13.
Gupta A, Bajaj NS. Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient. J Nucl Cardiol 2018;25:150-2.PubMed
14.
American Society of Nuclear Cardiology. MedAxiom Nuclear Survey. J Nucl Cardiol 2014;21:5-88.
15.
Lindner O, Burchert W, Buechel R, Schäfer WM, Im Namen der Arbeitsgemeinschaft „Kardiovaskuläre Nuklearmedizin“ der Deutschen Gesellschaft für Nuklearmedizin under AG20 „Nuklearkardiologische Diagnostik“ der Deutschen Gesellschaft für Kardiologie. Myocardial Perfusion SPECT 2018 in Germany: Results of the 8th Survey. Nukl Nucl Med 2019;58(6):425-33.
16.
Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med 2009;50:1076.PubMed
17.
Nkoulou R, Fuchs TA, Pazhenkottil AP, Kuest SM, Ghadri JR, Stehli J, et al. Absolute myocardial blood flow and flow reserve assessed by gated SPECT with cadmium-zinc-telluride detectors using 99mTc-tetrofosmin: head-to-head comparison with 13 N-ammonia PET. J Nucl Med 2016;57:1887-92.PubMed
18.
Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti J-J, et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: Head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging 2018;45:1079-90.PubMedPubMedCentral
19.
20.
21.
Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET. Eur J Nucl Med Mol Imaging 2011;38:1908-16.PubMed
22.
Bravo PE, Pozios I, Pinheiro A, Merrill J, Tsui BMW, Wahl RL, et al. Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 2012;110:1033-9.PubMedPubMedCentral
23.
Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc Imaging 2015;8:438-47.PubMed
24.
Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De Bondt P, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging 2015;42:1929-40.PubMedPubMedCentral
25.
Iskandrian AS, Heo J, Askenase A, Segal BL, Auerbach N. Dipyridamole cardiac imaging. Am Heart J 1988;115:432-43.PubMed
26.
27.
Lortie M, Beanlands RSB, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007;34:1765-74.PubMed
28.
Leppo JA, Meerdink DJ. Comparison of the myocardial uptake of a technetium-labeled isonitrile analogue and thallium. Circ Res 1989;65:632-9.PubMed
29.
Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 1996;37:1701-12.PubMed
30.
31.
Trochu J-N, Zhao G, Post H, Xu X, Belardinelli L, Belloni FL, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003;41:132-9.PubMed
32.
Hudgens S, Breeze J, Spalding J. Patient- and clinician-reported satisfaction with pharmacological stress agents for single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). J Med Econ 2013;16:828-34.PubMed
33.
Zhao G, Linke A, Xu X, Ochoa M, Belloni F, Belardinelli L, et al. Comparative profile of vasodilation by CVT-3146, ael A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003;307:182-9.PubMed
34.
Buhr C, Gössl M, Erbel R, Eggebrecht H. Regadenoson in the detection of coronary artery disease. Vasc Health Risk Manag 2008;4:337-40.PubMedPubMedCentral
35.
Husain Z, Palani G, Cabrera R, Karthikeyan AS, Dhanalakota S, Pathmanathan S, et al. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging 2012;28:1841-9.PubMed
36.
Bouallçgue FB, Nganoa C, Vigne J, Agostini D, Manrique A. Comparative performances of dipyridamole and regadenoson to detect myocardial ischemia using cardiac cadmium-zinc-telluride single-photon emission computerized tomography. J Clin Imaging Sci 2018;8:51.PubMed
37.
Assaad M, Berry A, Palanisamy J, Fenner J, Zughaib M. Differential effect of regadenoson versus dipyridamole on heart rate in patients with left bundle branch block: How does it affect the results of pharmacological nuclear stress testing? JRSM Cardiovasc Dis 2019;8:2048004019828257.PubMedPubMedCentral
38.
Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, ael selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75.PubMed
39.
Cullom SJ, Case JA, Courter SA, McGhie AI, Bateman TM. Regadenoson pharmacologic rubidium-82 PET: A comparison of quantitative perfusion and function to dipyridamole. J Nucl Cardiol 2013;20:76-83.PubMed
40.
Vasu S, Bandettini WP, Hsu L-Y, Kellman P, Leung S, Mancini C, et al. Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole: A study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2013;24:85.
41.
DiBella EVR, Fluckiger JU, Chen L, Kim TH, Pack NA, Matthews B, et al. The effect of obesity on regadenoson-induced myocardial hyperemia: A quantitative magnetic resonance imaging study. Int J Cardiovasc Imaging 2012;28:1435-44.PubMed
42.
Stolker JM, Lim MJ, Shavelle DM, Morris DL, Angiolillo DJ, Guzman LA, et al. Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory. Cardiovasc Revascularization Med Mol Interv 2015;16:266-71.
43.
Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20.PubMed
44.
van Nunen LX, Lenders GD, Schampaert S, van’t Veer M, Wijnbergen I, Brueren GRG, et al. Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement. EuroInterv J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol 2015;11:905-13.
45.
Potier L, Chequer R, Roussel R, Mohammedi K, Sismail S, Hartemann A, et al. Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus. Cardiovasc Diabetol 2018;17:11.PubMedPubMedCentral
46.
Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387-93.PubMed
47.
Fang Y-HD, Liu Y-C, Ho K-C, Kuo F-C, Yang C-F, Yen T-C, et al. Single-scan rest/stress imaging with 99mTc-Sestamibi and cadmium zinc telluride-based SPECT for hyperemic flow quantification: A feasibility study evaluated with cardiac magnetic resonance imaging. PLoS ONE 2017;12:e0183402.PubMedPubMedCentral
48.
49.
Murthy VL, Lee BC, Sitek A, Naya M, Moody J, Polavarapu V, et al. Comparison and prognostic validation of multiple methods of quantification of myocardial blood flow with 82Rb PET. J Nucl Med 2014;55:1952-8.PubMed
50.
51.
Wells RG, Marvin B, Poirier M, Renaud J, deKemp RA, Ruddy TD. Optimization of SPECT measurement of myocardial blood flow with corrections for attenuation, motion, and blood binding compared with PET. J Nucl Med 2017;58:2013-9.PubMed
52.
Amer KA, Hurren JR, Edwin SB, Cohen G. Regadenoson versus dipyridamole: A comparison of the frequency of adverse events in patients undergoing myocardial perfusion imaging. Pharmacotherapy 2017;37:657-61.PubMed
53.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Lancet Respir Med 2015;3:631-9.PubMed
Metadaten
Titel
Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera
verfasst von
Quentin Brana
Frédérique Thibault, MD
Maxime Courtehoux, MD
Gilles Metrard, MD
Maria Joao Ribeiro, MD, PhD
Denis Angoulvant, MD, PhD
Matthieu Bailly, MD
Publikationsdatum
10.07.2020
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 1/2022
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-020-02271-5

Weitere Artikel der Ausgabe 1/2022

Journal of Nuclear Cardiology 1/2022 Zur Ausgabe

Editorial

Promises and pitfalls of relying on angiography-derived indexes to identify myocardial ischemia: A tale of Romulus and Remus

Editorial

How can we take creative research a step further?

ORIGINAL ARTICLE

Insights into Nuclear Cardiology in the United States from the first 3 years of the ImageGuide Registry

ORIGINAL ARTICLE

Transluminal attenuation gradient derived from coronary CT angiography to predict ischemia in SPECT myocardial perfusion imaging: Effect of coronary cross-sectional area

ORIGINAL ARTICLE

Assessment of different quantification metrics of [18F]-NaF PET/CT images of patients with abdominal aortic aneurysm

EDITORIAL

Molecular imaging of free radicals for anthracycline-induced cardiotoxicity: See the burn?

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise